A Study of ASP2215 (Gilteritinib) Combined With Atezolizumab in Patients With Relapsed or Treatment Refractory FMS-like Tyrosine Kinase (FLT3) Mutated Acute Myeloid Leukemia (AML)

Inclusion Criteria: * Subject is considered an adult according to local regulation at the time of signing informed consent form (ICF). * Subject has defined AML by the World Health Organization (WHO) criteria (2017) and fulfills one of the following: * Refractory to at least 1 cycle of induction chemotherapy * Relapsed after achieving remission with a prior therapy * Subject is positive for FLT3 mutation in bone marrow or blood after completion of the subject's last interventional treatment. * Subject has an Eastern Cooperative Oncology Group (ECOG) performance status ≤ 2 at screening. * Subject must meet the following criteria as indicated on the clinical laboratory tests: * Serum Aspartate aminotransferase (AST) and Alanine Aminotransferease (ALT) ≤ 2.5 x upper limit of normal (ULN) * Serum total bilirubin (TBL) ≤ 1.5 x ULN * Serum creatinine ≤ 1.5 x ULN or an estimated glomerular filtration rate of \> 50 mL/min as calculated by the Modification of Diet in Renal Disease equation. * Subject is suitable for oral administration of study drug. * A female subject is eligible to participate if she is not pregnant and at least one of the following conditions applies: * Not a woman of childbearing potential (WOCBP) OR * WOCBP who agrees to follow the contraceptive guidance throughout the treatment period and for at least 180 days after the final study drug administration. * Female subject must agree not to breastfeed starting at screening and throughout the study …